Pfizer AdComm Asks Many Questions About COVID Vaccine For Ages 5-11, But Gets Few Answers

Often data was not available from FDA, CDC or the sponsor to answer subgroup, safety and other questions that could have influenced the outcome of the advisory committee meeting.

Handful of question marks
One unanswered question from the advisory committee was on whether children age 5 to 11 will need a booster shot after the primary series. • Source: Alamy

Pfizer Inc. and BioNTech SE’s COVID-19 vaccine gained a largely positive recommendation for use in children age 5 to 11 despite many unanswered questions on potentially influential topics.

More from US FDA Performance Tracker

More from Regulatory Trackers